Business

Mass. Mover

Coronado Biosciences stock continues to fall

Mike McCready of Pearl Jam posed with his bobble head, made for supporters of the Crohn’s foundation.

Associated Press/File 2013

Mike McCready of Pearl Jam posed with his bobble head, made for supporters of the Crohn’s foundation.

Advertisement

Monday was a devastating day for Coronado Biosciences Inc. — its stock fell 67 percent — and Tuesday just rubbed it in with a 10 percent decline. The Burlington company’s phase 2 clinical trial for its treatment of Crohn’s disease, an immune disorder that causes bowel inflammation, ended badly. Coronado hoped to show that whipworm parasites could be used to trick a Crohn’s patient’s immune system into attacking the worms instead of the intestines. The trial did not meet a primary goal of significantly improving a measure of Crohn’s severity or a secondary goal of achieving remission.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com